The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
|Videos|May 21, 2014
The Prognostic Value of CRP in HCC
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.
Advertisement
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective study to determine the prognostic value of C-reactive protein (CRP) levels in patients with hepatocellular carcinoma (HCC) who are undergoing treatment with sorafenib.
Clinical Pearls:
- Results showed that high CRP levels imply a worse outcome with regard to progression-free survival and overall survival in patients that were being treated with sorafenib
- These results should not be looked at too deeply, since the study was retrospective and part of a small series
- As physicians learn more about HCC and the different markers, CRP is intriguing because of the interest in anti-inflammatory drugs
Advertisement
Related to this article
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
In patients 45+ with papillary thyroid cancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification.
Selpercatinib achieved a 53% objective response rate in pediatric patients with RET-altered solid tumors, with no treatment discontinuations due to treatment-related adverse events in LIBRETTO-121.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5